These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28182271)

  • 1. Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.
    Dagogo-Jack I; Shaw AT; Riely GJ
    Clin Pharmacol Ther; 2017 May; 101(5):625-633. PubMed ID: 28182271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
    D'Arcangelo M; Wynes MW; Hirsch FR
    Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
    Katayama R; Lovly CM; Shaw AT
    Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
    Cheng M; Ott GR
    Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
    Boi M; Zucca E; Inghirami G; Bertoni F
    Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK-immunoreactive neoplasms.
    Minoo P; Wang HY
    Int J Clin Exp Pathol; 2012; 5(5):397-410. PubMed ID: 22808292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
    Landi L; Cappuzzo F
    Expert Rev Clin Pharmacol; 2016; 9(2):203-14. PubMed ID: 26582431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.
    Amin AD; Rajan SS; Liang WS; Pongtornpipat P; Groysman MJ; Tapia EO; Peters TL; Cuyugan L; Adkins J; Rimsza LM; Lussier YA; Puvvada SD; Schatz JH
    Cancer Res; 2015 Jul; 75(14):2916-27. PubMed ID: 26018086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.
    Katayama R
    Pharmacol Ther; 2017 Sep; 177():1-8. PubMed ID: 28185914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
    Kaczmar J; Mehra R
    Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
    Franco R; Rocco G; Marino FZ; Pirozzi G; Normanno N; Morabito A; Sperlongano P; Stiuso P; Luce A; Botti G; Caraglia M
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):407-20. PubMed ID: 23560836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK inhibitors and advanced non-small cell lung cancer (review).
    Rossi A; Maione P; Sacco PC; Sgambato A; Casaluce F; Ferrara ML; Palazzolo G; Ciardiello F; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):499-508. PubMed ID: 24889366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
    Klempner SJ; Ou SH
    Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
    Roskoski R
    Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
    Solomon B; Wilner KD; Shaw AT
    Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.